TY - JOUR
T1 - Intranasal Nerve Growth Factor administration improves cerebral functions in a child with severe traumatic brain injury: A case report
AU - Chiaretti, Antonio
AU - Conti, Giorgio
AU - Falsini, Benedetto
AU - Buonsenso, Danilo
AU - Crasti, Matteo
AU - Manni, Luigi
AU - Soligo, Marzia
AU - Fantacci, Claudia
AU - Genovese, Orazio
AU - Calcagni, Maria Lucia
AU - Di Giuda, Daniela
AU - Mattoli, Maria Vittoria
AU - Cocciolillo, Fabrizio
AU - Ferrara, Pietro
AU - Ruggiero, Antonio
AU - Staccioli, Susanna
AU - Colafati, Giovanna Stefania
AU - Riccardi, Riccardo
PY - 2017
Y1 - 2017
N2 - Background: Nerve growth factor (NGF) promotes neural recovery after experimental traumatic brain injury (TBI) supporting neuronal growth, differentiation and survival of brain cells and up-regulating the neurogenesis-associated protein Doublecortin (DCX). Only a few studies reported NGF administration in paediatric patients with severe TBI. Methods: A four-year-old boy in a persistent unresponsive wakefulness syndrome (UWS) was treated with intranasal murine NGF administration 6 months after severe TBI. The patient received four cycles of intranasal NGF (0.1 mg/kg, twice a day for 10 consecutive days). Results: NGF administration improved functional [Positron Emission Tomography/Computed Tomography (PET/CT); Single photon emission/Computed Tomography (SPECT/CT) and Magnetic Resonance Imaging (MRI)] assessment, electrophysiological [Electroencephalogram (EEG) and Visual Evoked Potential (VEP)] studies and clinical conditions. He showed improvements in voluntary movements, facial mimicry, phonation, attention and verbal comprehension, ability to cry, cough reflex, oral motility, feeding capacity, and bowel and urinary functions. After NGF administration, raised levels of both NGF and DCX were found in the cerebrospinal fluid of the patient. No side effects were reported. Conclusions: Although further studies are needed for better understanding the neuroprotective role of this neurotrophin, intranasal NGF administration appears to be a promising and safe rescuing strategy treatment in children with neurological impairment after TBI.
AB - Background: Nerve growth factor (NGF) promotes neural recovery after experimental traumatic brain injury (TBI) supporting neuronal growth, differentiation and survival of brain cells and up-regulating the neurogenesis-associated protein Doublecortin (DCX). Only a few studies reported NGF administration in paediatric patients with severe TBI. Methods: A four-year-old boy in a persistent unresponsive wakefulness syndrome (UWS) was treated with intranasal murine NGF administration 6 months after severe TBI. The patient received four cycles of intranasal NGF (0.1 mg/kg, twice a day for 10 consecutive days). Results: NGF administration improved functional [Positron Emission Tomography/Computed Tomography (PET/CT); Single photon emission/Computed Tomography (SPECT/CT) and Magnetic Resonance Imaging (MRI)] assessment, electrophysiological [Electroencephalogram (EEG) and Visual Evoked Potential (VEP)] studies and clinical conditions. He showed improvements in voluntary movements, facial mimicry, phonation, attention and verbal comprehension, ability to cry, cough reflex, oral motility, feeding capacity, and bowel and urinary functions. After NGF administration, raised levels of both NGF and DCX were found in the cerebrospinal fluid of the patient. No side effects were reported. Conclusions: Although further studies are needed for better understanding the neuroprotective role of this neurotrophin, intranasal NGF administration appears to be a promising and safe rescuing strategy treatment in children with neurological impairment after TBI.
KW - Arts and Humanities (miscellaneous)
KW - Developmental and Educational Psychology
KW - Doublecortin
KW - Nerve Growth Factor
KW - Neurology (clinical)
KW - Neuroscience (miscellaneous)
KW - intranasal administration
KW - traumatic brain injury
KW - Arts and Humanities (miscellaneous)
KW - Developmental and Educational Psychology
KW - Doublecortin
KW - Nerve Growth Factor
KW - Neurology (clinical)
KW - Neuroscience (miscellaneous)
KW - intranasal administration
KW - traumatic brain injury
UR - http://hdl.handle.net/10807/119561
U2 - 10.1080/02699052.2017.1376760
DO - 10.1080/02699052.2017.1376760
M3 - Article
SN - 0269-9052
VL - 31
SP - 1538
EP - 1547
JO - Brain Injury
JF - Brain Injury
ER -